Authors: Surbone, A

Citation: A. Surbone, Why writing on ethics in oncology, CR R ONC H, 40(2), 2001, pp. 95-96

Authors: Surbone, A

Citation: A. Surbone, Ethical implications of genetic testing for breast cancer susceptibility, CR R ONC H, 40(2), 2001, pp. 149-157

Authors: Surbone, A

Citation: A. Surbone, Too early to say that pregnancy has an antitumor effect on breast cancer, J CL ONCOL, 19(16), 2001, pp. 3707-3708

Authors: D'Andrea, G Fennelly, D Norton, L Baselga, J Gilewski, T Hudis, C Moynahan, ME Raptis, G Sklarin, N Surbone, A Theodoulou, M Templeton, MA Yao, TJ Seidman, AD

Citation: G. D'Andrea et al., Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer, CLIN CANC R, 5(2), 1999, pp. 275-279

Authors: Hudis, C Fornier, M Riccio, L Lebwohl, D Crown, J Gilewski, T Surbone, A Currie, V Seidman, A Reichman, B Moynahan, M Raptis, G Sklarin, N Theodoulou, M Weiselberg, L Salvaggio, R Panageas, KS Yao, TJ Norton, L

Citation: C. Hudis et al., 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study, J CL ONCOL, 17(4), 1999, pp. 1118-1126

Authors: Hudis, C Seidman, A Baselga, J Raptis, G Lebwohl, D Gilewski, T Moynahan, M Sklarin, N Fennelly, D Crown, JPA Surbone, A Uhlenhopp, M Riedel, E Yao, TJ Norton, L

Citation: C. Hudis et al., Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy, J CL ONCOL, 17(1), 1999, pp. 93-100